• Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
Money Profit News
No Result
View All Result
Home Breaking News

Pfizer says its Covid pill with HIV drug cuts the risk of hospitalization or death by 89%

by
November 5, 2021
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Related Posts

Home prices cool in January, even falling in some cities, S&P Case-Shiller says

Lululemon shares jump as holiday-quarter sales surge

Sam Bankman-Fried paid over $40 million to bribe at least one official in China, DOJ alleges

Pence ordered to testify in probe of Trump’s efforts to overturn 2020 election

A person walks past the Pfizer building in New York City, March 2, 2021.

Carlo Allegri | Reuters

Pfizer said Friday that its easy-to-administer Covid-19 pill, used in combination with a widely used HIV drug, cut the risk of hospitalization or death by 89% in high-risk adults who’ve been exposed to the virus.

It’s now the second antiviral pill behind Merck‘s to demonstrate strong effectiveness for treating Covid at the first sign of illness. If cleared by regulators, it would likely be a game changer in the ongoing global pandemic fight. Pfizer said it plans to submit its data to the Food and Drug Administration “as soon as possible.”

Pfizer’s pill, scientifically known as PF-07321332, is part of a class of medicines called protease inhibitors and works by inhibiting an enzyme the virus needs to replicate in human cells. Protease inhibitors are used to treat other viral pathogens such as HIV and hepatitis C.

The HIV drug helps slow the metabolism, or breakdown, of Pfizer’s pill in order for it to remain active in the body for longer periods of time at higher concentrations, the company said.

The company said its data on the drug is based on a mid-to-late stage study of 1,219 adults who had at least one underlying medical condition and a laboratory-confirmed infection within a five-day period. Participants were also given a low dose of ritonavir, a medication commonly used in combination treatments for HIV.

Pfizer said there were six hospitalizations and zero deaths out of the 607 trial participants who received the pill in combination with the HIV drug within five days of symptom onset. That compares with 41 hospitalizations and 10 deaths out of the 612 people who received a placebo.

“These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patients’ lives, reduce the severity of COVID-19 infections, and eliminate up to nine out of ten hospitalizations,” Pfizer CEO Albert Bourla said in a statement.

Unlike Gilead Sciences‘ intravenous drug remdesivir, Pfizer’s and Merck’s drugs can be taken by mouth. While vaccinations remain the best form of protection against the virus, health experts hope pills like these will keep the disease from progressing in those who do get infected and prevent trips to the hospital.

Merck and Ridgeback Biotherapeutics said Oct. 1 that they’ve developed a drug that, when administered alone, reduces the risk of hospitalization or death by around 50% for patients with mild or moderate cases of Covid.

The antiviral pill made by Merck was approved by Britain’s medicines regulator on Thursday.

June Raine, chief executive of the U.K.’s Medicines and Healthcare products Regulatory Agency, said that Merck’s pill will greatly facilitate the treatment of Covid, a disease that has killed more than 5 million people globally and caused tremendous strain on health systems.

Bourla told CNBC in April that Pfizer’s pill could be available to Americans by the end of this year.

Next Post

Insider buying: Big moves from Intel leaders highlight this week's top five internal stock purchases

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:

By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

Popular Posts

Breaking News

Home prices cool in January, even falling in some cities, S&P Case-Shiller says

by
March 28, 2023
0

A "For Sale" sign outside of a home in Atlanta, Georgia, on Friday, Feb. 17, 2023. Dustin Chambers | Bloomberg...

Read more

Home prices cool in January, even falling in some cities, S&P Case-Shiller says

Nvidia will be the ‘grand marshal’ of the A.I. bubble ‘parade,’ says Josh Brown

Pence ordered to testify in probe of Trump’s efforts to overturn 2020 election

Sam Bankman-Fried paid over $40 million to bribe at least one official in China, DOJ alleges

Lululemon shares jump as holiday-quarter sales surge

Apple launches its Pay Later service

Load More

All rights reserved by www.moneyprofitnews.com

  • Home
  • Breaking News
  • Privacy Policy
  • Email Whitelisting
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

moneyprofitnews